Immunocore Holdings (IMCR) Common Equity (2022 - 2025)
Historic Common Equity for Immunocore Holdings (IMCR) over the last 4 years, with Q3 2025 value amounting to $396.6 million.
- Immunocore Holdings' Common Equity rose 495.91% to $396.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $396.6 million, marking a year-over-year increase of 495.91%. This contributed to the annual value of $360.7 million for FY2024, which is 220.34% down from last year.
- Per Immunocore Holdings' latest filing, its Common Equity stood at $396.6 million for Q3 2025, which was up 495.91% from $388.5 million recorded in Q2 2025.
- Immunocore Holdings' Common Equity's 5-year high stood at $396.6 million during Q3 2025, with a 5-year trough of $338.9 million in Q4 2022.
- In the last 4 years, Immunocore Holdings' Common Equity had a median value of $368.8 million in 2023 and averaged $369.8 million.
- In the last 5 years, Immunocore Holdings' Common Equity skyrocketed by 883.44% in 2023 and then plummeted by 220.34% in 2024.
- Over the past 4 years, Immunocore Holdings' Common Equity (Quarter) stood at $338.9 million in 2022, then grew by 8.83% to $368.8 million in 2023, then dropped by 2.2% to $360.7 million in 2024, then increased by 9.94% to $396.6 million in 2025.
- Its Common Equity was $396.6 million in Q3 2025, compared to $388.5 million in Q2 2025 and $378.5 million in Q1 2025.